Investigating how lung function affects exercise performance in trained individuals
Role of Lung Function, Airway Inflammation and Bronchial Hyper Reactivity for Exercise Capacity in Well-trained Individuals
NA · University of Copenhagen · NCT06077019
This study is testing if using certain inhalers can improve how well young, physically active people can perform during exercise by looking at their lung function.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 39 Years |
| Sex | All |
| Sponsor | University of Copenhagen (other) |
| Locations | 1 site (Copenhagen) |
| Trial ID | NCT06077019 on ClinicalTrials.gov |
What this trial studies
This project aims to explore the relationship between lung function and exercise capacity in physically active individuals aged 18-39. Participants will undergo prolonged inhalation of beta2-agonists, specifically vilanterol combined with fluticasone furoate or indacaterol combined with mometasone furoate, alongside a placebo group. The study will assess how these interventions impact exercise performance, particularly focusing on maximal oxygen consumption. The findings could provide insights into optimizing exercise capacity through respiratory interventions.
Who should consider this trial
Good fit: Ideal candidates are physically active individuals aged 18-39 who engage in more than 5 hours of exercise weekly and have high maximal oxygen consumption.
Not a fit: Patients with severe asthma or other significant respiratory issues, as well as those with certain chronic illnesses or who smoke, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance exercise performance strategies for well-trained individuals by optimizing lung function.
How similar studies have performed: While the specific combination of interventions may be novel, similar studies investigating lung function and exercise performance have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18-39 * Physically active \> 5 h weekly * Maximal oxygen consumption classified as high or very high Exclusion Criteria: * Diagnosed with severe asthma and been in treatment with long-acting beta2-agonist/corticosteroid * ECG abnormality * ACQ score \> 1.5 * Severe bronchial hyperreactivity as determined by mannitol test * FEV1/FVC ratio \< 0.7 determined with spirometry * Chronic illness determined to be a potential risk for participant during study * In chronic treatment with medication that may interfere with study results * Pregnancy * Smoker * Blood donation during the past 3 months
Where this trial is running
Copenhagen
- August Krogh Building — Copenhagen, Denmark (RECRUITING)
Study contacts
- Principal investigator: Morten Hostrup, PhD — University of Copenhagen
- Study coordinator: Morten Hostrup, PhD
- Email: mhostrup@nexs.ku.dk
- Phone: +4535321595
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Exercise Performance